In Reply to Onal et al

Affiliations

¹ Royal Marsden NHS Foundation Trust, London, UK; Faculty of Medicine, University of Queensland, Brisbane, Australia.
² Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK.
³ Royal Marsden NHS Foundation Trust, London, UK.

Comment

L Nicholls et al. Clin Oncol (R Coll Radiol). 2022 Apr.

. 2022 Apr;34(4):e173.

doi: 10.1016/j.clon.2022.01.009. Epub 2022 Jan 31.

¹ Royal Marsden NHS Foundation Trust, London, UK; Faculty of Medicine, University of Queensland, Brisbane, Australia.
² Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK.
³ Royal Marsden NHS Foundation Trust, London, UK.

No abstract available

Comment on

Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L, Chapman E, Khoo V, Suh YE, Tunariu N, Wang Y, van As N. Nicholls L, et al. Clin Oncol (R Coll Radiol). 2022 Jan;34(1):63-69. doi: 10.1016/j.clon.2021.10.004. Epub 2021 Oct 29. Clin Oncol (R Coll Radiol). 2022. PMID: 34756755
Re: Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Onal C, Oymak E, Guler OC. Onal C, et al. Clin Oncol (R Coll Radiol). 2022 Apr;34(4):e171-e172. doi: 10.1016/j.clon.2021.12.013. Epub 2021 Dec 30. Clin Oncol (R Coll Radiol). 2022. PMID: 34973870 No abstract available.